PMOS Carries a Psychiatric Burden That Extends Well Beyond Reproduction
The condition once called polycystic ovary syndrome now carries a new name in endocrine circles: polyendocrine metabolic ovarian syndrome, or PMOS. The label reflects what clinicians have long seen at the bedside — this is not only a reproductive disorder, but a multisystem condition with metabolic, dermatologic, and psychiatric consequences. Among those consequences, depression and anxiety stand out as the most clinically consistent and most easily missed.
The psychiatric burden is not subtle. In women with PMOS, mood symptoms often sit alongside irregular cycles, infertility concerns, acne, weight gain, and hirsutism, creating a clinical picture in which emotional distress can be mistaken for a secondary reaction rather than a core component of illness. When mental health symptoms are folded into the disorder itself, screening becomes part of endocrine care rather than an optional add-on.
Depression Rates Are Consistently Higher Than in Controls
A recent meta-analysis of 35 studies included 5,857 women, with 3,610 affected by PCOS/PMOS and 2,247 controls. Across different assessment tools, depressive symptoms were markedly more common in the PMOS group. Using the Beck Depression Inventory, prevalence reached 42.11% versus 13.62% in controls. With the Hospital Anxiety and Depression Scale, rates were 28.90% versus 15.80%. On the Patient Health Questionnaire, prevalence was 26.50% versus 9.10%, although this comparison did not reach statistical significance.
In broad terms, women with PMOS were about two to three times as likely to report depressive symptoms as women without the disorder. Those are clinically meaningful differences, especially because many of these patients present first to gynecology, endocrinology, or primary care rather than to psychiatry. When depressive symptoms accumulate around chronic uncertainty, body image distress, fertility concerns, and metabolic change, the syndrome can become self-reinforcing: inflammation, insulin resistance, sleep disruption, and stress reactivity may each intensify the others.
Anxiety followed a similar pattern. Using the Hospital Anxiety and Depression Scale, anxiety symptoms were reported in 48.25% of women with PMOS versus 31.40% of controls. The comparison did not reach statistical significance in that analysis, but the direction of effect aligned with the broader literature. A prior meta-analysis of 57 studies and 172,040 patients found increased odds of a clinical diagnosis of depression, anxiety, and obsessive compulsive disorder in women with PMOS. The odds ratios were 2.79 for depression, 2.75 for anxiety, and 1.37 for OCD.
Low- and Middle-Income Countries Show Even Higher Symptom Prevalence
The psychiatric burden appears heavier in low- and middle-income countries, where access to routine screening and specialist mental health care is often limited. A separate meta-analysis focused on these settings found depression in 51% of women with PCOS/PMOS and anxiety in 45%.
Age and geography shaped the estimates further. The highest prevalence of both depression and anxiety appeared among women aged 20 to 25 years, with depression at 63% and anxiety at 56%. Studies conducted in India reported similarly elevated rates, with depression at 55% and anxiety at 51%.
Young adulthood is often when reproductive concerns, relationship stress, social comparison, and career pressure collide with the first visible signs of PMOS. In health systems with limited access to mental health professionals, those symptoms may go untreated for long periods, even when the patient is repeatedly seen for menstrual irregularity, weight gain, or fertility evaluation. The result is a diagnostic gap that can widen over time.
Bipolar Disorder and Other Psychiatric Diagnoses Also Enter the Differential
The psychiatric associations are not limited to depression and anxiety. A systematic review and meta-analysis of 11 studies, involving 73,102 women with PCOS/PMOS and 340,724 controls, found an approximately twofold increase in risk for bipolar disorder. Across the included studies, the reported odds varied widely, from 0.98 to 8.78, which suggests substantial heterogeneity in methods and populations.
One smaller study found PCOS/PMOS in about 30% of drug-naïve patients with bipolar disorder, compared with about 10% in the general population. Among those treated long term with valproic acid, prevalence rose to 53%. That observation raises an important clinical question about overlapping endocrine vulnerability, medication effects, and bidirectional risk. Valproic acid is already known to affect weight and ovarian function in some patients, so the intersection with PMOS deserves careful monitoring rather than casual attribution.
Emerging links have also been described with attention-deficit/hyperactivity disorder, eating disorders, and schizophrenia. Those associations remain less consistent, but they reinforce a central clinical message: psychiatric assessment in PMOS should not stop at a depression screen alone.
Exercise Helps, but It Does Not Replace Psychiatric Treatment
Lifestyle treatment remains a cornerstone of PMOS management because it addresses metabolic risk, ovulatory dysfunction, and general cardiometabolic health. It may also help mood. A 2026 meta-analysis of randomized controlled trials found that structured exercise significantly reduced depressive symptoms in women with PCOS/PMOS.
The likely mechanism is biologically plausible. Regular physical activity can improve insulin sensitivity, reduce inflammatory signaling, stabilize sleep, and support self-efficacy, all of which may soften depressive symptoms. Yet the effect should be viewed as adjunctive. Exercise can complement treatment for major depression or anxiety, but it is not a substitute for evidence-based psychiatric care when a patient meets diagnostic criteria for a mood or anxiety disorder.
A patient who is struggling with infertility, visible androgenic symptoms, weight stigma, or irregular cycles may benefit from movement-based interventions and coaching, but she may also need psychotherapy, antidepressant treatment, or coordinated specialty referral. Treating only the endocrine features risks leaving a major determinant of quality of life untouched.
Routine Screening Should Be Built Into PMOS Care
The practical takeaway is straightforward. Depression and anxiety screening should become routine in endocrine and reproductive visits for women with PMOS. That applies even when the presenting complaint is “only” irregular menses or fertility planning, because psychiatric symptoms can be present before they are volunteered.
Screening is especially important in low-resource settings, where stigma and limited access to mental health services can prevent timely diagnosis. Culturally tailored counseling matters, particularly when fertility concerns, appearance-related distress, and family expectations intersect with chronic illness. Multidisciplinary care models offer the most coherent path forward because they align endocrine treatment, psychiatric assessment, and lifestyle support in a single framework.
For clinicians, the message is simple: PMOS is a medical condition with psychiatric consequences that are common, measurable, and treatable. For patients, the message should be equally direct: mood and anxiety symptoms are not a side issue, and they deserve attention as part of routine PMOS care. The next unanswered question is how best to scale integrated screening and treatment in settings where both endocrine and mental health resources remain fragmented.